Menu
  • Join
  • Login
  • Contact
 

Search abstracts


The proportion and influential factors for patients who switch from ticagrelor to clopidogrel

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: HUA, Yiming (China Taiwan)
  • Co-author(s): Chiu-Ju Chen: Department of Pharmacy, Chi Mei Medical Center, Tainan City, Taiwan, Province of China
    Yi Ming Hua: Department of Pharmacy, Chi Mei Medical Center, Tainan City, Taiwan, Province of China
    Hui Chen Su: Department of Pharmacy, Chi Mei Medical Center, Tainan City, Taiwan, Province of China
  • Abstract:

    Background

    According to ESC and AHA guideline, Dual Anti-Platelet Therapy (DAPT) with Aspirin and P2Y12 receptor antagonist, such as Ticagrelor, is the gold therapy for patients with Acute Coronary Syndromes (ACS). In Taiwan, Ticagrelor is covered by Health insurance for 9 months. 

    Purpose

    The prescription rate of Ticagrelor seems less than..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses